Gaceta Médica de México, Год журнала: 2024, Номер 160(4)
Опубликована: Дек. 27, 2024
Язык: Английский
Human Vaccines & Immunotherapeutics, Год журнала: 2024, Номер 20(1)
Опубликована: Июнь 5, 2024
Recombinant protein vaccines represent a well-established, reliable and safe approach for pandemic vaccination. SpikoGen® is recombinant spike trimer manufactured in insect cells formulated with Advax-CpG55.2 adjuvant. In murine, hamster, ferret non-human primate studies, consistently provided protection against range of SARS-CoV-2 variants. A pivotal Phase 3 placebo-controlled efficacy trial involving 16,876 participants confirmed the ability to prevent infection severe disease caused by virulent Delta strain. subsequently received marketing authorization from Iranian FDA early October 2021 prevention COVID-19 adults. Following successful pediatric study, its approval was extended children 5 years older. Eight million doses have been delivered, next-generation booster version currently development. This highlights benefits adjuvanted protein-based approaches which should not overlook when vaccine platforms are being selected future pandemics.
Язык: Английский
Процитировано
6
Frontiers in Microbiology, Год журнала: 2024, Номер 15
Опубликована: Июнь 13, 2024
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December with staggering economic fallout and human suffering. The unique structure of SARS-CoV-2 its underlying pathogenic mechanism were responsible for the global pandemic. In addition to direct damage virus, triggers an abnormal immune response leading a cytokine storm, culminating distress other fatal diseases that pose significant challenge clinicians. Therefore, potential treatments should focus not only on eliminating virus but also alleviating or controlling immune/inflammatory responses. Current management strategies COVID-19 include preventative measures supportive care, while role host progression has largely been overlooked. Understanding interaction between receptors, as well pathogenesis, proven be helpful prevention, early recognition progression, vaccine development, interventions aimed at reducing immunopathology have shown reduce adverse clinical outcomes improve prognosis. Moreover, several key mutations genome sequence result enhanced binding affinity cell receptor, produce escape, either increased transmissibility virulence variants carry these mutations. This review characterizes structural features SARS-CoV-2, variants, their system, emphasizing dysfunctional responses storm progression. Additionally, therapeutic options are reviewed, providing critical insights into management, exploring effective approaches deal public health crises SARS-CoV-2.
Язык: Английский
Процитировано
6
Pathogens and Global Health, Год журнала: 2024, Номер 118(6), С. 453 - 458
Опубликована: Июнь 17, 2024
In the fourth year of COVID-19 occurrence, a new variant, JN.1, has emerged and spread globally become dominant strain in several regions. It some specific mutations its spike proteins, empowering it with higher transmissibility. Regarding significance issue, understanding clinical immunological traits JN.1 is critical for enhancing health strategies vaccination efforts globally, ultimate goal bolstering our collective response to pandemic. this study, we take look at latest findings characteristics as well consequences on bypassing immune system. We demonstrate importance continual surveillance strategic adaptation within healthcare frameworks along wastewater sampling rapid identification emerging SARS-CoV-2 variants.
Язык: Английский
Процитировано
5
One Health Bulletin, Год журнала: 2025, Номер unknown
Опубликована: Янв. 23, 2025
Objective: To evaluate the effectiveness of COVID-19 vaccines in preventing symptomatic and severe diseases among adults aged 60 years older, identify key risk factors that influence infection severity, explore strategies to enhance protection for this high-risk group. Methods: A test-negative case-control study was conducted individuals comprising 300 COVID- 19-positive cases COVID-19-negative controls. Data on vaccination status other variables were collected via telephone interviews using a pre-tested questionnaire. Vaccine calculated as 1 minus crude odds ratio (OR), with 95% confidence interval (CI). Additionally, univariate logistic regression multivariable employed associated SARS-CoV-2 disease severity. Results: Among 600 participants, 13.7% (82/600) identified unvaccinated individuals. Multivariable analysis revealed vaccinated only factor determining both (adjusted OR 2.63; CI: 1.57-4.41) severity 1.85; 1.00-3.62). The estimated vaccine 68.0% (95% CI : 0.45-0.82) fully 59.0% 0.30-0.76) partially Of cases, 22.0% (66/300) severe. demonstrated an 73.0% 0.47-0.86) against 0.44-0.83) Conclusions: older is lower than anticipated. In addition administration booster doses, interventions such higher adjuvants, intradermal routes should be evaluated protect highly vulnerable group at greatest adverse outcomes.
Язык: Английский
Процитировано
0
Therapeutic Advances in Infectious Disease, Год журнала: 2025, Номер 12
Опубликована: Янв. 1, 2025
The emergence of the COVID-19 JN.1 variant has raised global health concerns as it gains prevalence in several regions worldwide. First identified August 2023, evolved from Omicron lineage's BA.2.86 subvariant. Patients infected with commonly exhibit symptoms such sore throat, fever, dry cough, nausea, and vomiting. While World Health Organization labeled a Variant Interest, currently presents low risk. However, its increased transmissibility, particularly cold, climates, is concerning. This review provides comprehensive overview JN.1's biological characteristics, epidemiology, immune evasion, efficacy existing antiviral treatments vaccination strategies. A literature search across key databases targeted studies January 2023 to 2024, emphasizing recent insights into spread clinical impact. Findings reveal that exhibits higher infectivity evasion than previous variants, largely due L4555 mutation. From November March showed an increasing trend transmission. Previously approved antivirals, including Paxlovid, Veklury, Lagevrio, demonstrate effectiveness against JN.1, current vaccines still protect severe illness this variant. rates remain low. Monitoring efforts include genomic assessments, wastewater surveillance, digital tracking contain variant's spread. It essential encourage public maintain preventive measures reduce Continued research critical for understanding managing evolving landscape emerging variants.
Язык: Английский
Процитировано
0
Frontiers in Cellular and Infection Microbiology, Год журнала: 2025, Номер 15
Опубликована: Фев. 11, 2025
Objective In January 2023, China implemented the “Class B Management” policy, marking a new phase in COVID-19 control. As SARS-CoV-2 variants continue to emerge, some have shown significant immune evasion, posing challenges epidemic control efforts. To manage pandemic effectively, Henan Province launched surveillance program for variants, systematically analyzing their clinical characteristics and epidemiological patterns. Methods This study collected genomic sequence data from 5,965 cases between 1, March 17, 2024, using variant system. Genome analysis was performed with CLC Genomics Workbench, genotyping alignment were carried out Nextclade platform. The severity of different assessed relation patient sex, age, classification, vaccination status. Results Between Week 1 2023 11 total complete genome sequences obtained, including 3,004 male (50.36%) 2,961 female (49.64%) cases. majority mild (5,451 cases, 91.38%), followed by moderate (311 5.21%) severe or critical (203 3.4%). predominant included BA.5.2, XBB, BA.2.86. BA.5.2 dominant until April after which it gradually replaced XBB. From December BA.2.86 began increase became 2024. XBB exhibited significantly lower rate most infections being ( P < 0.05). Male patients, elderly, certain (e.g., BA.5.2) associated more outcomes, while showed pathogenicity, marked reduction fatal Conclusion evolve, incidence has progressively decreased. Both exhibit pathogenicity. provides vital scientific evidence on features, manifestations, strategies variants. It underscores importance continuous viral sequencing guide public health decision-making.
Язык: Английский
Процитировано
0
Vaccines, Год журнала: 2025, Номер 13(4), С. 424 - 424
Опубликована: Апрель 17, 2025
Vaccination has been instrumental in curbing the transmission of SARS-CoV-2 and mitigating severity clinical manifestations associated with COVID-19. Numerous COVID-19 vaccines have developed to this effect, including BioNTech-Pfizer Moderna’s mRNA vaccines, as well adenovirus vector-based such Oxford–AstraZeneca. However, emergence new variants subvariants SARS-CoV-2, characterized by enhanced transmissibility immune evasion, poses significant challenges efficacy current vaccination strategies. In review, we aim comprehensively outline landscape emerging concern (VOCs) sub-lineages that recently surfaced post-pandemic years. We assess effectiveness existing their booster doses, against these subvariants, BA.2-derived sub-lineages, XBB BA.2.86 (Pirola). Furthermore, discuss latest advancements vaccine technology, multivalent pan-coronavirus approaches, along development several next-generation coronavirus exosome-based, virus-like particle (VLP), mucosal, nanomaterial-based vaccines. Finally, highlight key critical areas for future research address evolving threat develop strategies combating viral threats, thereby improving preparedness pandemics.
Язык: Английский
Процитировано
0
Human Immunology, Год журнала: 2024, Номер 85(6), С. 111117 - 111117
Опубликована: Сен. 13, 2024
Язык: Английский
Процитировано
3
Biomedical engineering, Год журнала: 2024, Номер unknown
Опубликована: Апрель 29, 2024
In this chapter, we delve into the pivotal role of molecular docking in realm computational biology and chemistry, focusing specifically on its application drug discovery targeting SARS-CoV-2. Molecular docking, a critical technique, has played significant predicting interactions bindings molecules, particularly concerning SARS-CoV-2’s main protease RNA polymerase. This chapter highlights synergy between virtual screening, emphasizing expedited identification evaluation potential candidates against Through comprehensive discussion, aim to provide nuanced understanding rapid advancements for SARS-CoV-2, accentuating indispensable value tools methods contemporary therapeutic development.
Язык: Английский
Процитировано
1
International Journal of Surgery, Год журнала: 2024, Номер 110(9), С. 5955 - 5956
Опубликована: Май 29, 2024
aDepartment of Respiratory Medicine, Shaoxing Second Hospital, Zhejiang, China bClinical Science Institute, University Hospital Galway, Ireland We declare no competing interests. Not applicable: (Our submission is a letter-to-the-editor) Authorship: Sponsorships or interests that may be relevant to content are disclosed at the end this article. Published online ■ *Corresponding Author Address: Clinical Newcastle Road, H91 YR71, Ireland, Tel: +353 091-495-0743. E-mail address: [email protected] (D. Shan). This an open access article distributed under Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided original work properly cited. http://creativecommons.org/licenses/by/4.0/
Язык: Английский
Процитировано
1